Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...

The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad's molecular ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

New research suggests a genetic mutation previously believed to promote esophageal cancer might actually play a protective ...

Boston-based Dana-Farber Cancer Institute has launched the Center for RAS Therapeutics, aiming to study and develop drug therapies for RAS-driven cancers.

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Black Diamond Therapeutics shows promise with BDTX-1535 for NSCLC treatment. Click here to find out why I rate BDTX stock a ...

Many cancers, including PDAC, are driven by mutations in the RAS family of oncogenes – genes that, when altered, promote cancer. Researchers have long sought drugs that target the actions of mutant ...

The evidence that recurrent SNVs or CDNs are common in true cancer driver genes is convincing, with more limited evidence that many more undiscovered cancer driver mutations will have CDNs, and that ...